Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Acquisitions & Divestments (2018 - 2022)

Spero Therapeutics' Change in Acquisitions & Divestments history spans 5 years, with the latest figure at $49.9 million for Q2 2022.

  • For Q2 2022, Change in Acquisitions & Divestments rose 143.27% year-over-year to $49.9 million; the TTM value through Mar 2023 reached $49.9 million, down 11.66%, while the annual FY2022 figure was $60.8 million, 17.9% up from the prior year.
  • Change in Acquisitions & Divestments reached $49.9 million in Q2 2022 per SPRO's latest filing, up from $10.9 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $50.6 million in Q1 2019 to a low of $2.0 million in Q4 2020.
  • Average Change in Acquisitions & Divestments over 5 years is $20.7 million, with a median of $18.3 million recorded in 2020.
  • Peak YoY movement for Change in Acquisitions & Divestments: crashed 85.61% in 2020, then skyrocketed 351.2% in 2021.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $35.5 million in 2018, then crashed by 76.03% to $8.5 million in 2019, then tumbled by 76.47% to $2.0 million in 2020, then soared by 250.0% to $7.0 million in 2021, then surged by 612.44% to $49.9 million in 2022.
  • Per Business Quant, the three most recent readings for SPRO's Change in Acquisitions & Divestments are $49.9 million (Q2 2022), $10.9 million (Q1 2022), and $7.0 million (Q4 2021).